PQRI Case Study (2): Functional Equivalence for Equipment Replacements - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PQRI Case Study (2): Functional Equivalence for Equipment Replacements
The second in a series of eight case studies from the Product Quality Research Institute focuses on functional equivalence for equipment.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 72-75

Risk identification, analysis, and evaluation


Figure 1: Fault-tree analysis (FTA) of equipment changes and associated validation impact. (ALL FIGURES ARE COURTESY OF THE AUTHORS)
The risk-assessment process began with a review and analysis of the change control system to determine how equipment parts replacements could potentially cause an unwanted or undetected change to the equipment's validated state. The analysis was organized into the fault-tree structure (see Figure 1). This fault tree illustrates the potential means by which equipment changes, such as parts replacements, could pose risk to the validated state of the equipment. The team concluded that many of the potential fault pathways were already being appropriately mitigated by robust quality systems (e.g., training, validation, and change control) that were performing as intended and that were being routinely audited. However, significant gaps and improvement opportunities were noted around the process used for the functional-equivalence assessments (see Figure 1, yellow pathway).


Figure 2: Fault-tree analysis (FTA) of functional equivalent assessments.
To further explore the risks associated with the functional-equivalence assessment process for equipment replacement parts, the risk-assessment team continued development of the fault tree as shown in Figure 2. The team focused on two key areas of risk: functional-equivalence assessments performed by parts vendors, and functional-equivalence assessments performed internally by the firm's functional areas.

The detailed FTA executed by the risk-assessment team revealed two areas of significant risk where improvement was required:
  • The Initiator (i.e., petitioner and preliminary data collector) for functional-equivalence evaluations should be a subject matter expert (SME) who is appropriately trained and qualified to craft accurate initial assessments (see Figure 2, green triangles).
  • Specific roles and responsibilities for each functional area participating in functional-equivalence assessments should be clearly defined (see Figure 2, beige triangles).

Risk control

For each of the two areas of significant risk identified in the FTAs and summarized above, associated risk-control plans were established, as follows:

Training curricula were created to define the training and qualification criteria for personnel initiating functional-equivalence assessments. These controls were designed to ensure that Initiators would be able to identify, compile, and/or generate the data and rationale required to support thorough and accurate functional-equivalence assessments.

Roles and responsibilities for each functional area participating in functional-equivalence assessments were delineated in the form of executable checklists designed to ensure that every functional-equivalence assessment will be performed in a thorough and reproducible fashion. Each organization identified in Figure 2 (Engineering, Technical Services, Quality Assurance, and Regulatory) created a checklist tailored to their specific roles and responsibilities that the team had collectively defined.


Table I: Checklist template for determining engineering functional equivalence.
This approach minimized both gaps and redundancies in the assessment efforts while also providing a common assessment record format to facilitate overall review of the assessment package. Each functional area checklist details unique areas of consideration for the assessment and provides spaces for the assessment conclusions and the signatures of the assessor(s). An example checklist from the Engineering functional area is shown in Table I.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here